NCT07096713 (Anti-VEGF) is a NA clinical trial of Intervention 1: Brolucizumab in Anti-VEGF Therapy, sponsored by Benha University.

Who is sponsoring NCT07096713?

NCT07096713 is sponsored by Benha University.

What drugs are being tested in NCT07096713?

Interventions in NCT07096713: Intervention 1: Brolucizumab, Intervention 2: Aflibercept.

What condition does NCT07096713 study?

NCT07096713 studies Anti-VEGF Therapy.

Is NCT07096713 still recruiting?

NCT07096713 is currently completed. Last updated 31 July 2025.

Last reviewed 2025-07-31 · How we verify

NCT07096713: Anti-VEGF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema

Completed NA Last updated 31 July 2025

What this trial tests

NA trial testing Intervention 1: Brolucizumab in Anti-VEGF Therapy in 38 participants. Completed in 1 June 2024.

Timeline

1 January 2024

Primary endpoint
1 June 2024

1 June 2024

Quick facts

Lead sponsor	Benha University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	1 January 2024
Primary completion	1 June 2024
Estimated completion	1 June 2024
Sites	1 location across Egypt

Drugs / interventions tested

Intervention 1: Brolucizumab — full drug profile →
Intervention 2: Aflibercept — full drug profile →

Conditions studied

Anti-VEGF Therapy — all drugs for Anti-VEGF Therapy →

Sponsor

Benha University

Who can join

Eligibility, any sex, with Anti-VEGF Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This retrospective, comparative cohort study included 38 eyes from 38 patients with center-involving diabetic macular edema (DME), treated at Benha University Hospital. Patients were divided into two groups: 19 eyes received intravitreal Brolucizumab (6 mg), and 19 eyes received intravitreal Aflibercept (2 mg), with the aim of comparing their efficacy and safety over a 6-month period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Benha University trials

Trials by the same sponsor.

NCT07526675 — Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer · NA · not yet recruiting
NCT07480031 — Determination of the Optimal Inspiratory Pressure to Decrease Incidence of Gastric Insufflation With Adequate Ventilatio · NA · not yet recruiting
NCT07465185 — Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery · Phase 2 · recruiting
NCT07467356 — Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip · Phase 3 · recruiting
NCT07300787 — miRNA in Pediatric Gastritis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07096713 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Benha University
Last refreshed: 31 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07096713.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing